The predecessor of Sanjing Pharmaceutical is the state-owned Harbin Pharmaceutical Factory No. 3. It was founded in 1950. It initially produced intramuscular and intravenous water injections. It is the earliest specialized production of water injections in Heilongjiang Province and the earliest in China. An enterprise that has introduced foreign continuous production equipment for water injections. After decades of training in pharmaceutical production and operation, the company has developed from a single dosage form to a comprehensive pharmaceutical enterprise with multiple varieties, multiple dosage forms, pharmaceutical raw materials and preparations. It mainly produces and operates more than 20 dosage forms and more than 300 specifications and varieties such as injections, oral liquids, tablets, capsules, granules, and freeze-dried powder injections, forming a rich product lineup. It has four varieties worth over 100 million yuan and 12 varieties worth over 10 million yuan. Its leading products include calcium gluconate (OTC drugs), zinc gluconate (health products), Shuanghuanglian Oral Liquid (OTC drugs), Sileping (prescription drugs), etc. In 2004, nearly 100 million yuan was invested to establish an open R&D platform with international standards. On February 25, 2004, the "Sanjing" brand was recognized as a "China Famous Trademark" by the State Administration for Industry and Commerce. On December 13, 2004, the Sanjing brand was valued at RMB 4.003 billion as authorized by the Beijing Famous Brand Asset Appraisal Company. In 2001, Sanjing Pharmaceutical took the lead in implementing the second restructuring within Harbin Pharmaceutical Group and transformed into a limited company. Since then, it has started low-cost expansion. It acquired the Mingshui County Pharmaceutical Factory in Heilongjiang Province that year, and in the following years, it successively launched low-cost enterprises in the province. It acquired a number of pharmaceutical companies such as Heihe, Sunwu, and Hegang, and completed the adjustment and construction of production layout. In 2002, we began to establish pharmaceutical commercial companies, and successively established more than a dozen commercial companies in the country through brand grafting, forming a marketing network with Sanjing characteristics. In 2003, in order to realize the linkage between the product market and the capital market, we planned to reorganize the listed company "Swan Shares", and realized the "backdoor listing" in 2004. In 2005, we completed the subsequent reorganization, sold out the cement assets, and exchanged the pharmaceutical equity. The merger of parent and subsidiary companies was realized. In September 2005, it was officially renamed Harbin Pharmaceutical Group Sanjing Pharmaceutical Co., Ltd. At present, the company's main business is clear and its assets are of excellent quality. It has basically completed the industrial layout of a general drug production base, a traditional Chinese medicine production base, a health care product production base, a children's drug production base, and an API production base. It will gradually end the investment period and enter the growth stage. , becoming a solid foundation for the company's future development and an important economic growth point. As of May 2006, Sanjing Pharmaceutical has developed into a large-scale group pharmaceutical listed company with 30 joint-stock and holding subsidiaries. It has the conditions and foundation to use the functions of the capital market to integrate other pharmaceutical resources, in order to further expand its business. Strong provides new protection.

2005 was the first full fiscal year after the company completed its restructuring and listing, and the company's main business profitability increased significantly. In 2005, the company achieved main business income of 1.769 billion yuan, a year-on-year increase of 175.24%; main business profit of 827 million yuan, a year-on-year increase of 216.19%; total profit of 252.56 million yuan, a year-on-year increase of 566.51%; net profit of 145.14 million yuan, a year-on-year increase 443.70%.

The company had a good start in 2006. In the first quarter, it achieved main business income of 523.79 million yuan, main business profit of 211.08 million yuan, and net profit of 60.03 million yuan, a year-on-year increase of 9.15%, 4.70%, and 185.3% respectively. .